The Zhitong Finance App learned that BOX International released a research report stating that it maintained the “buy” rating of Deqi Pharmaceuticals (06996) and raised its revenue forecast for 2023 to 410 million yuan. Based on the DCF model valuation, the target price was raised to HK$4.6. The company reached an agreement with Hanson Pharmaceuticals (03692) on the domestic commercialization of celinisol. The bank believes that this cooperation will help accelerate hospital coverage and market penetration in Seliniso, and help Deqi Pharmaceutical save marketing costs.
交银国际：维持德琪医药(06996)“买入”评级 目标价升至4.6港元
BOB International: Maintaining Deqi Pharmaceuticals (06996)'s “Buy” Rating, Raising the Target Price to HK$4.6
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.